BNTX - Moderna: Only For Aggressive Investors

• The short-term thesis for investing in Moderna is the belief that the company will continue to profit from its COVID-19 vaccine because of booster shots.
• The long-term thesis for investing in Moderna is the belief that the company has more success to come from a promising vaccine pipeline.
• Moderna has transformed over the past year from a money losing R&D-focused biotech to a profitable commercial company.
• With a PS of 60.65 and a PE of nearly 331, there is little doubt that Moderna sells at an extremely high valuation for a stock that is still somewhat speculative.
• Only the most aggressive investors willing to hold the stock for +5 years should consider buying the stock at the current price.

For further details see: